Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11.

Article  CAS  PubMed  Google Scholar 

Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol. 2005;87:163–208.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of non-Hodgkin’s lymphoma. Med Sci (Basel, Switzerland). 2021;9(1):5.

Google Scholar 

Sallam Y, Gaber A, Shaheen A, Zeeneldin A. Non-anthracycline chemotherapy associated with a poor outcome in elderly Egyptian patients with diffuse large B-cell non-Hodgkin lymphoma. J Cancer Metastasis Treatment. 2015;1(2):76.

Article  Google Scholar 

Yoon N, Ahn S, Yoo HY, Kim SJ, Kim WS, Ko YH. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm. Oncotarget. 2017;8(13):22014–22.

Article  PubMed  PubMed Central  Google Scholar 

Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor κB activity is required for survival of activated B cell–like diffuse large B cell lymphoma cells. J Exp Med. 2001;194(12):1861–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boudesco C, Verhoeyen E, Martin L, Chassagne-Clement C, Salmi L, Mhaidly R, et al. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization. Blood. 2018;132(5):510–20.

Article  CAS  PubMed  Google Scholar 

Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373–84.

Article  CAS  PubMed  Google Scholar 

Lee JH, Jeong H, Choi JW, Oh HE, Kim YS. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis. Sci Rep. 2017;7(1):1785.

Article  PubMed  PubMed Central  Google Scholar 

Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115–21.

Article  CAS  PubMed  Google Scholar 

Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci. 2013;110(4):1398–403.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bohers E, Mareschal S, Bouzelfen A, Marchand V, Ruminy P, Maingonnat C, et al. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. Genes Chromosom Cancer. 2014;53(2):144–53.

Article  CAS  PubMed  Google Scholar 

Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A, et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res. 2012;18(19):5203–11.

Article  CAS  PubMed  Google Scholar 

Pham-Ledard A, Cappellen D, Martinez F, Vergier B, Beylot-Barry M, Merlio JP. MYD88 Somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type. J Investig Dermatol. 2012;132(8):2118–20.

Article  CAS  PubMed  Google Scholar 

Fernández-Rodríguez C, Bellosillo B, García-García M, Sánchez-González B, Gimeno E, Vela MC, et al. MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma. Leukemia. 2014;28(10):2104–6.

Article  PubMed  Google Scholar 

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373–80.

Article  CAS  PubMed  Google Scholar 

Abdelhamid T, Samra M, Ramadan H, Mehessin M, Mokhtar N. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: A retrospective study. J Egypt Natl Canc Inst. 2011;23(1):17–24.

Article  PubMed  Google Scholar 

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86.

Article  PubMed  Google Scholar 

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82.

Article  CAS  PubMed  Google Scholar 

Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121(11):2051–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martínez-Trillos A, Pinyol M, Navarro A, Aymerich M, Jares P, Juan M, et al. Regular Article LYMPHOID NEOPLASIA Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood. 2014;123(24):3790–6.

Article  PubMed  Google Scholar 

Weber ANR, Cardona Gloria Y, Çınar Ö, Reinhardt HC, Pezzutto A, Wolz OO. Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities. Cancer Immunol Immunother. 2018;67(11):1797–807.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Staiger AM, Ott MM, Parmentier S, Rosenwald A, Ott G, Horn H, et al. Allele-specific PCR is a powerful tool for the detection of the MYD88 L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samples. Br J Haematol. 2015;171(1):145–8.

Article  CAS  PubMed  Google Scholar 

Rovira J, Karube K, Valera A, Colomer D, Enjuanes A, Colomo L, et al. MYD88 L265P mutations, but no other variants, identify a subpopulation of DLBCL patients of activated B-cell origin, extranodal involvement, and poor outcome. Clin Cancer Res. 2016;22(11):2755–64.

Article  CAS  PubMed  Google Scholar 

Kraan W, Horlings HM, van Keimpema M, Schilder-Tol EJM, Oud MECM, Scheepstra C, et al. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J. 2013;3(9):e139–e139.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim Y, Ju H, Kim DH, Yoo HY, Kim SJ, Kim WS, et al. CD79B and MYD88 mutations in diffuse large B-cell lymphoma. Hum Pathol. 2014;45(3):556–64.

Article  CAS  PubMed  Google Scholar 

Caner V, Sen Turk N, Baris IC, Cetin GO, Tepeli E, Hacioglu S, et al. MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas. Genet Test Mol Biomarkers. 2015;19(7):372–8.

Article  CAS  PubMed  Google Scholar 

Vermaat JS, Somers SF, De Wreede LC, Kraan W, De Groen RAL, Schrader AMR, et al. MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis. Haematologica. 2020;105(2):424–34.

Article  CAS  PubMed